Tom Powles

10.1k total citations · 1 hit paper
80 papers, 2.7k citations indexed

About

Tom Powles is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tom Powles has authored 80 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 41 papers in Surgery and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tom Powles's work include Bladder and Urothelial Cancer Treatments (23 papers), Viral-associated cancers and disorders (22 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Tom Powles is often cited by papers focused on Bladder and Urothelial Cancer Treatments (23 papers), Viral-associated cancers and disorders (22 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Tom Powles collaborates with scholars based in United Kingdom, France and United States. Tom Powles's co-authors include Mark Bower, Mark Nelson, Brian Gazzard, Justin Stebbing, Sundhiya Mandalia, Tom Newsom‐Davis, R.T.D. Oliver, Maria De Santis, Silke Gillessen and Christina Thirlwell and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Tom Powles

77 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2021 309 citations Tom Powles, Joaquim Bellmunt et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Tom Powles

Since Specialization

Citations

This map shows the geographic impact of Tom Powles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Powles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Powles more than expected).

Fields of papers citing papers by Tom Powles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Powles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Powles. The network helps show where Tom Powles may publish in the future.

Co-authorship network of co-authors of Tom Powles

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Powles. A scholar is included among the top collaborators of Tom Powles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Powles. Tom Powles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Penile cancer: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up 2024 ·ESMO Open ·(unknown), Marco Bandini, Éva Compérat, Gert De Meerleer, Karim Fizazi, Jourik A. Gietema, Silke Gillessen, Alex Kirkham, (unknown), Constantine Alifrangis, Tom Powles	6
2	LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4) 2024 ·Annals of Oncology ·(unknown), Félix Guerrero‐Ramos, (unknown), (unknown), Rohan Garje, Tom Powles, Colleen Peyton, (unknown), Ja Hyun Ku, (unknown), (unknown), (unknown), (unknown), Chao Gong, (unknown), (unknown), (unknown), Sumeet Bhanvadia, Hussein Sweiti, Sarah P. Psutka	4
3	2408TiP DISCUS: A randomised phase II study of 3 vs 6 cycles of chemotherapy followed by maintenance avelumab in advanced urothelial cancer - Wearable devices and circulating biomarkers assessing quality of life and surrogate efficacy endpoints 2023 ·Annals of Oncology ·Francesca Jackson‐Spence, (unknown), Javier Puente, Javier Molina‐Cerrillo, Syed A. Hussain, Charlotte Ackerman, (unknown), (unknown), Yohann Loriot, Tom Powles, Enrique Grande Pulido	1
4	2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC) 2023 ·Annals of Oncology ·Petros Grivas, Srikala S. Sridhar, Begoña P. Valderrama, (unknown), Yohann Loriot, (unknown), Damien Pouessel, Michiel S. van der Heijden, Matthew D. Galsky, Shuchi Gulati, Alain Ravaud, Elisa Fontana, Alexander I. Spira, Benjamin A. Gartrell, Amir Mortazavi, Nicolás Isambert, (unknown), Tom Powles, (unknown), Rafael Morales‐Barrera	2
5	1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011 2022 ·Annals of Oncology ·(unknown), (unknown), (unknown), Su‐Jin Shin, S.H. Park, Vagif Atduev, (unknown), (unknown), Petros Grivas, Ronald de Wit, Arlene O. Siefker‐Radtke, (unknown), Peter H. O’Donnell, Tom Powles, Jacqueline Vuky, Yujie Zhao, (unknown), Sonia Franco, Blanca Homet Moreno, (unknown)	0
6	LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313) 2022 ·Annals of Oncology ·Toni K. Choueiri, Tom Powles, Laurence Albigès, (unknown), (unknown), (unknown), (unknown), Marco Maruzzo, (unknown), Luis Fein, Fabio A. Schutz, Daniel Yick Chin Heng, (unknown), (unknown), Yih‐Leong Chang, (unknown), C. Suárez Rodríguez, Robert J. Motzer	16
7	1760P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100 2022 ·Annals of Oncology ·Jeanny B. Aragon‐Ching, Petros Grivas, (unknown), Joaquim Bellmunt, (unknown), (unknown), Alessandra di Pietro, Tom Powles, Srikala S. Sridhar	5
8	Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma 2018 ·Nature Reviews Urology ·Tom Powles, (unknown)	25
9	TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma 2017 ·Annals of Oncology ·Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, (unknown), (unknown), (unknown), Jillian L. Astarita, Rafael Cubas, Suchit Jhunjhunwala, Yanling Yang, Yasin Şenbabaoğlu, (unknown), Yohann Loriot, Ira Mellman, (unknown), Priti S. Hegde, Richard Bourgon, Tom Powles	8
10	Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC) 2017 ·Annals of Oncology ·Aristotelis Bamias, Kimon Tzannis, (unknown), Lauren C. Harshman, Simon J. Crabb, (unknown), Sumanta K. Pal, Ugo De Giorgi, Sylvain Ladoire, (unknown), Edward Yu, Günter Niegisch, C. Sternberg, (unknown), Ulka N. Vaishampayan, Andrea Necchi, (unknown), Tom Powles, Joaquim Bellmunt, Matt D. Galsky	1
11	CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma 2016 ·Cancer Research ·Andrew Feber, (unknown), Ankur Chakravarthy, Patricia de Winter, Kunal Shah, Manit Arya, Muhammad Saqib, Raj Nigam, Peter R. Malone, Wei Shen Tan, Simon Rodney, Alex Freeman, Charles Jameson, Gareth A. Wilson, Tom Powles, Stephan Beck, Tim R. Fenton, Tyson V. Sharp, Asıf Muneer, John D. Kelly	45
12	Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study 2016 ·Annals of Oncology ·Yohann Loriot, Jonathan E. Rosenberg, Tom Powles, Andrea Necchi, Syed A. Hussain, Rafael Morales, Margitta Retz, Günter Niegisch, Ignacio Durán, Christine Théodore, José Luis Perez‐Gracia, Enrique Grande Pulido, (unknown), (unknown), Sanjeev Mariathasan, Oyewale O. Abidoye, (unknown)	19
13	Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when 2012 ·Expert Review of Anticancer Therapy ·Axel Bex, Tom Powles	8
14	UK guidelines for the systemic treatment of renal cell carcinoma 2009 ·British Journal of Hospital Medicine ·Paul Nathan, John Wagstaff, Emilio Porfiri, Tom Powles, Tim Eisen	6
15	The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease 2009 ·Annals of Oncology ·Tom Powles, Justin Stebbing, A. Bazeos, Eleftheria Hatzimichael, Sundhiya Mandalia, Mark Nelson, Brian Gazzard, Mark Bower	116
16	Molecular Positron Emission Tomography and PET/CT Imaging in Urological Malignancies 2007 ·European Urology ·Tom Powles, Iain Murray, Cathryn Brock, R.T.D. Oliver, Norbert Avril	110
17	A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours 2007 ·Annals of Oncology ·Jonathan Shamash, Tom Powles, (unknown), Peter Wilson, Wendy Ansell, Elaine M. Walsh, Daniel M. Berney, Justin Stebbing, T. Oliver	22
18	Significance of Variation Within HIV, EBV, and KSHV Subtypes 2006 ·Journal of the International Association of Physicians in AIDS Care ·Justin Stebbing, Tom Powles, Mark Nelson, Mark Bower	2
19	Assessing the size and stage of testicular germ cell tumours: 1984–2003 2005 ·British Journal of Urology ·(unknown), Tom Powles, Daniel M. Berney, Suhail Baithun, Vinod H. Nargund, R.T.D. Oliver	25
20	HIV-Associated Anal Cancer 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Mark Bower, Tom Powles, Tom Newsom‐Davis, Christina Thirlwell, Justin Stebbing, S Mandalia, Mark Nelson, Brian Gazzard	140

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact